Abstract
Bladder cancer accounted for 4.6% of all cancer diagnoses and 2.9% of cancer-related deaths in the United States in 2019. The initial evaluation for locally advanced and/or metastatic bladder cancer requires collaboration between specialists in urology, medical oncology, radiation oncology, pathology, and radiology. Although cisplatin-containing regimens are the preferred first-line treatment for metastatic bladder cancer, selecting the patients most likely to benefit from their use has remained a challenge. In fact, as many as 50% of patients are considered cisplatin ineligible after clinical evaluation. Treatment with cisplatin requires careful monitoring and surveillance. Treatment-related toxicities are common, and thorough patient assessment should be conducted at each patient encounter. Periodic surveillance imaging should be obtained at regular intervals to assess for disease response.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7–34.
von der Maase H, Sengelov L, Roberts JT, Ricci S, Dogliotti L, Oliver T, Moore MJ, Zimmermann A, Arning M. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol. 2005;23(21):4602–8.
Lue TF, JW MA, editors. Smith & Tanagho’s general urology. New York: McGraw-Hill Medical; 2013.
Galsky MD, Hahn NM, Rosenberg J, Sonpavde G, Hutson T, Oh WK, Dreicer R, Vogelzang N, Sternberg C, Bajorin DF, Bellmunt J. A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy. Lancet Oncol. 2011;12(3):211–4.
Galsky MD, Hahn NM, Rosenberg J, Sonpavde G, Hutson T, Oh WK, Dreicer R, Vogelzang N, Sternberg CN, Bajorin DF, Bellmunt J. Treatment of patients with metastatic urothelial cancer “unfit” for cisplatin-based chemotherapy. J Clin Oncol. 2011;29(17):2432–8.
Bellmunt J, Mottet N, De Santis M. Urothelial carcinoma management in elderly or unfit patients. EJC Suppl. 2016;14(1):1.
De Santis M, Bellmunt J, Mead G, Kerst JM, Leahy M, Maroto P, Gil T, Marreaud S, Daugaard G, Skoneczna I, Collette S. Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. J Clin Oncol. 2012;30(2):191.
Sternberg CN, De Mulder PH, Schornagel JH, Theodore C, Fossa SD, Van Oosterom AT, Witjes F, Spina M, Van Groeningen CJ, De Balincourt C, Collette L. Randomized phase III trial of high–dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol No. 30924. J Clin Oncol. 2001;19(10):2638–46.
Colevas AD, Setser A. The NCI common terminology criteria for adverse events (CTCAE) v 3.0 is the new standard for oncology clinical trials. J Clin Oncol. 2004;22(14_suppl):6098.
Crawford J, Althaus B, Armitage J, Balducci L, Bennett C, Blayney DW, Cataland SR, Dale DC, Demetri GD, Erba HP, Foran J. Myeloid growth factors: clinical practice guidelines in oncology™. JNCCN J Natl Compr Canc Netw. 2007;5(2):188–202.
Manohar S, Leung N. Cisplatin nephrotoxicity: a review of the literature. J Nephrol. 2018;31(1):15–25.
Mols F, Beijers T, Vreugdenhil G, van de Poll-Franse L. Chemotherapy-induced peripheral neuropathy and its association with quality of life: a systematic review. Support Care Cancer. 2014;22(8):2261–9.
Seretny M, Currie GL, Sena ES, Ramnarine S, Grant R, MacLeod MR, Colvin LA, Fallon M. Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis. Pain. 2014;155(12):2461–70.
Hershman DL, Lacchetti C, Dworkin RH, Lavoie Smith EM, Bleeker J, Cavaletti G, Chauhan C, Gavin P, Lavino A, Lustberg MB, Paice J. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2014;32(18):1941–67.
Albers JW, Chaudhry V, Cavaletti G, Donehower RC. Interventions for preventing neuropathy caused by cisplatin and related compounds. Cochrane Database Syst Rev. 2014;3:CD005228.
Berger MJ, Ettinger DS, Aston J, Barbour S, Bergsbaken J, Bierman PJ, Brandt D, Dolan DE, Ellis G, Kim EJ, Kirkegaard S. NCCN guidelines insights: antiemesis, version 2.2017. J Natl Compr Cancer Netw. 2017;15(7):883–93.
Arends J, Baracos V, Bertz H, Bozzetti F, Calder PC, Deutz NE, Erickson N, Laviano A, Lisanti MP, Lobo DN, McMillan DC. ESPEN expert group recommendations for action against cancer-related malnutrition. Clin Nutr. 2017;36(5):1187–96.
Mustian KM, Alfano CM, Heckler C, Kleckner AS, Kleckner IR, Leach CR, Mohr D, Palesh OG, Peppone LJ, Piper BF, Scarpato J. Comparison of pharmaceutical, psychological, and exercise treatments for cancer-related fatigue: a meta-analysis. JAMA Oncol. 2017;3(7):961–8.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2021 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Mille, P., Carsello, J. (2021). Metastatic Bladder Cancer and the Use of Cisplatin Chemotherapy. In: Trabulsi, E.J., Lallas, C.D., Lizardi-Calvaresi, A.E. (eds) Chemotherapy and Immunotherapy in Urologic Oncology. Springer, Cham. https://doi.org/10.1007/978-3-030-52021-2_16
Download citation
DOI: https://doi.org/10.1007/978-3-030-52021-2_16
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-52020-5
Online ISBN: 978-3-030-52021-2
eBook Packages: MedicineMedicine (R0)